Therapeutic Effect of the Intraperitoneal Cisplatin Installation (IPCI) in Advanced Gastric Carcinoma with Serosa Invasion Retrospective study.
- Author:
Haeng Su KIM
1
;
Jin Ho KWAK
;
Yong Ho KIM
;
Chang Hwan LEE
;
Jung Hwan YOOK
;
Seung Tae OH
;
Byung Sik KIM
;
Keun Chun PARK
Author Information
1. Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea. bskim@www.amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Stomach neoplasm;
Intraperitoneal cisplatin installation;
Peritoneal recurrence
- MeSH:
Chemotherapy, Adjuvant;
Cisplatin*;
Fluorouracil;
Follow-Up Studies;
Humans;
Operating Rooms;
Peritoneal Cavity;
Recurrence;
Retrospective Studies*;
Serous Membrane*;
Stomach Neoplasms;
Wounds and Injuries
- From:Journal of the Korean Cancer Association
2000;32(6):1015-1021
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We performed retrospective study to evaluate the preventive effect of intraperitoneal cisplatin installation (IPCI) on peritoneal recurrence after curative resection of advanced gastric cancer. MATERIALS AND METHODS: The effect of IPCI was evaluated in 297 advanced gastric carcinoma patients from January 1993 to December 1996. In IPCI group, 100 mg/body of cisplatin in one liter of saline was installed in peritoneal cavity before wound closure in operating room and drained out 2 hours later. Postoperative adjuvant chemotherapy with combination of 5-FU and cisplain was performed. 155 cases were treated by IPCI. Median follow-up period was 26 months. RESULTS: Out of 139 (46.8%) recurred cases, peritoneal, local and distant recurrences developed in 65 (37.8%) cases, 66 (38.4%) cases and 41 (23.8%) cases respectively. In univariated analysis for survival and recurrence, IPCI, T stage and N stage were significant prognostic factors. As regards to peritoneal recurrence, IPCI and T stage were significant factors. In multivariated survival analysis, as regards to recurrence, IPCI, T stage and N stage were significant prognostic factors. As regards to peritoneal recurrence, IPCI was the only significant independent prognostic factor. CONCLUSION: We concluded that IPCI can effectively prevent peritoneal recurrence and overall recurrence and it shows marginal survival benefit in advanced gastric cancer patients with serosa invasion.
